News

In The News Lindsay Bealor Greenleaf talks to Policy & Medicine about Azar’s plan to move drugs from Part B to D
In The News Lindsay Bealor Greenleaf talks to The Street about the Senate HELP Committee hearing on the Trump Administration’s Drug Pricing Blueprint
In The News Lindsay Bealor Greenleaf Discusses the Administration’s Drug Pricing Proposals and the Implications for Pharmacists with Drug Topics Magazine
In The News ADVI’s Marc Samuels on why moving drugs under the medical benefit to Medicare Part D is bad policy
In The News Lindsay Bealor Greenleaf Discusses PBMs with the Washington Post
In The News ADVI’s Lindsay Bealor Greenleaf Discusses President Trump’s Drug Pricing Plan with The Street
In The News 3 Ways Rx “Middlemen” May Have to Reform
In The News Lindsay Bealor Greenleaf talks to Fierce Healthcare about the Trump administration’s plan to reform the prescription drug supply chain
In The News LINDSAY BEALOR GREENLEAF TALKS TO PINK SHEET ABOUT THE PRESIDENT’S PENDING DRUG PRICING ANNOUNCEMENT